Pierre-Guillaume Poureau1,2,*, Jean-Philippe Metges2
Oncologie, Vol.23, No.1, pp. 47-59, 2021, DOI: 10.32604/Oncologie.2021.15525
Abstract Immunotherapy for digestive cancers is booming and for the first time an immune checkpoint inhibitor has been
granted marketing authorization for the treatment of digestive cancer. In order to better understand the mecanism of action of these treatments, their adverse events and the escape mecansim, it is necessary to know the fundamentals of cancer immunology. The innate and adaptive immune system allows the elimination of cancer cells
by direct non-specific cytotoxicity (Natural Killer cells), by the development of an adaptive cell-mediated response
(dendritic cells becoming antigen presenting cells, allowing the differentiation of lymphocytes naive in CD4 and
CD8 T lymphocytes)… More >